Literature DB >> 20162572

KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses.

Semra Demokan1, Xiaofei Chang, Alice Chuang, Wojciech K Mydlarz, Jatinder Kaur, Peng Huang, Zubair Khan, Tanbir Khan, Kimberly L Ostrow, Mariana Brait, Mohammad O Hoque, Nanette J Liegeois, David Sidransky, Wayne Koch, Joseph A Califano.   

Abstract

Silencing of tumor suppressor genes plays a vital role in head and neck carcinogenesis. In this study, we aimed to evaluate to the utility of aberrant promoter hypermethylation for detection in a panel of 10 genes (KIF1A, EDNRB, CDH4, TERT, CD44, NISCH, PAK3, VGF, MAL and FKBP4) in head and neck squamous cell carcinoma (HNSCC) via a candidate gene approach. We investigated methylation of the gene promoters by bisulfite modification and quantitative methylation-specific PCR (Q-MSP) in a preliminary study of a limited cohort of salivary rinses from healthy subjects (n = 61) and patients with HNSCC (n = 33). The methylation status of 2 selected genes (EDNRB and KIF1A) were then analyzed in 15 normal mucosa samples from a healthy population, 101 HNSCC tumors and the corresponding salivary rinses from 71 out of the 101 HNSCC patients were collected before treatment. The promoter regions of CDH4, TERT, VGF, MAL, FKBP4, NISCH and PAK3 were methylated in normal salivary rinses while no methylation of CD44 was observed in either normal salivary rinses or tumor samples. However, KIF1A and EDNRB were methylated in 98 and 97% of primary HNSCC tissues respectively and were only methylated in 2 and 6.6% of normal salivary rinses. In addition, KIF1A and EDNRB were methylated in 38 and 67.6% of salivary rinses from HNSCC patients, respectively. Promoter hypermethylation of KIF1A and EDNRB is a frequent event in primary HNSCC, and these genes are preferentially methylated in salivary rinses from HNSCC patients. KIF1A and EDNRB are potential biomarkers for HNSCC detection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162572      PMCID: PMC2946472          DOI: 10.1002/ijc.25248

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients.

Authors:  Ivy H N Wong; Jun Zhang; Paul B S Lai; Wan Y Lau; Y M Dennis Lo
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

2.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients.

Authors:  M Sanchez-Cespedes; M Esteller; L Wu; H Nawroz-Danish; G H Yoo; W M Koch; J Jen; J G Herman; D Sidransky
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.

Authors:  Li-Sung Hsu; Hsin-Chen Lee; Gar-Yang Chau; Pen-Hui Yin; Chin-Wen Chi; Wing Yiu Lui
Journal:  Oncol Rep       Date:  2006-02       Impact factor: 3.906

4.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.

Authors:  C Jerónimo; H Usadel; R Henrique; J Oliveira; C Lopes; W G Nelson; D Sidransky
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

5.  Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.

Authors:  S L Rosas; W Koch; M G da Costa Carvalho; L Wu; J Califano; W Westra; J Jen; D Sidransky
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

6.  Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma.

Authors:  Kwok-Wai Lo; Yuen-Shan Tsang; Joseph Kwong; Ka-Fai To; Peter M L Teo; Dolly P Huang
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

7.  Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.

Authors:  Janet C Lindsey; Meryl E Lusher; Jennifer A Anderton; Simon Bailey; Richard J Gilbertson; Andrew D J Pearson; David W Ellison; Steven C Clifford
Journal:  Carcinogenesis       Date:  2003-12-19       Impact factor: 4.944

Review 8.  Sensitive detection of DNA methylation.

Authors:  Susan E Cottrell; Peter W Laird
Journal:  Ann N Y Acad Sci       Date:  2003-03       Impact factor: 5.691

9.  Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.

Authors:  Mohammad Obaidul Hoque; Shahnaz Begum; Ozlem Topaloglu; Carmen Jeronimo; Elizabeth Mambo; William H Westra; J A Califano; David Sidransky
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  DCC promoter hypermethylation in esophageal squamous cell carcinoma.

Authors:  Hannah Lui Park; Myoung Sook Kim; Keishi Yamashita; William Westra; Andre Lopes Carvalho; Juna Lee; Wei-Wen Jiang; Jin Hyen Baek; Junwei Liu; Motonobu Osada; Chul-So Moon; Joseph A Califano; Masaki Mori; David Sidransky
Journal:  Int J Cancer       Date:  2008-06-01       Impact factor: 7.396

View more
  43 in total

Review 1.  Early progress in epigenetic regulation of endothelin pathway genes.

Authors:  A K Welch; M E Jacobs; C S Wingo; B D Cain
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Comprehensive mapping of the methylation landscape of 16 CpG-dense regions in oral and pharyngeal squamous cell carcinoma.

Authors:  Scott M Langevin; Damaris Kuhnell; Liang Niu; Jacek Biesiada; Yuet-Kin Leung; Ranjan Deka; Aimin Chen; Mario Medvedovic; Karl T Kelsey; Susan Kasper; Xiang Zhang
Journal:  Epigenomics       Date:  2019-06-19       Impact factor: 4.778

3.  Serum biomarkers for detection of head and neck squamous cell carcinoma.

Authors:  Wojciech K Mydlarz; Patrick T Hennessey; Hao Wang; Andre Lopez Carvalho; Joseph A Califano
Journal:  Head Neck       Date:  2015-06-26       Impact factor: 3.147

Review 4.  Epigenetics of oral and oropharyngeal cancers.

Authors:  Daniela Russo; Francesco Merolla; Silvia Varricchio; Giovanni Salzano; Giovanni Zarrilli; Massimo Mascolo; Viviana Strazzullo; Rosa Maria Di Crescenzo; Angela Celetti; Gennaro Ilardi
Journal:  Biomed Rep       Date:  2018-07-27

Review 5.  Clinical validity of saliva and novel technology for cancer detection.

Authors:  Karolina Elżbieta Kaczor-Urbanowicz; Fang Wei; Shannon Liu Rao; Jinseok Kim; Heebum Shin; Jordan Cheng; Michael Tu; David T W Wong; Yong Kim
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 6.  Molecular margins in head and neck cancer: Current techniques and future directions.

Authors:  Katelyn O Stepan; Michael M Li; Stephen Y Kang; Sidharth V Puram
Journal:  Oral Oncol       Date:  2020-07-20       Impact factor: 5.337

7.  Innovative rapid gene methylation analysis of surgical margin tissues in head and neck cancer.

Authors:  Masamichi Hayashi; Rafael Guerrero-Preston; Jun Okamura; Christina Michailidi; Zubair Kahn; Xiufeng Li; Julie Ahn; Marla Goldsmith; Wayne Koch
Journal:  Ann Surg Oncol       Date:  2014-03-27       Impact factor: 5.344

8.  Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion.

Authors:  Wei Li; Xinrui Liu; Bo Zhang; Dongxue Qi; Lihong Zhang; Yuhong Jin; Hongfa Yang
Journal:  J Exp Clin Cancer Res       Date:  2010-07-04

9.  Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study.

Authors:  Jong-Lyel Roh; Xin Victoria Wang; Judith Manola; David Sidransky; Arlene A Forastiere; Wayne M Koch
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

10.  High-incidence spontaneous tumors in JF1/Ms mice: relevance of hypomorphic germline mutation and subsequent promoter methylation of Ednrb.

Authors:  Junko Watanabe; Yasuhiko Kaneko; Masafumi Kurosumi; Yasuhito Kobayashi; Michihiro Sakamoto; Mitsuaki A Yoshida; Miho Akiyama; Yoshibumi Matsushima
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.